Vir Biotechnology (NYSE:VIR) EVP Herbert Virgin sold 7,900 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $47.99, for a total transaction of $379,121.00. Following the transaction, the executive vice president now owns 7,900 shares in the company, valued at approximately $379,121. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Herbert Virgin also recently made the following trade(s):

  • On Tuesday, July 14th, Herbert Virgin sold 7,900 shares of Vir Biotechnology stock. The stock was sold at an average price of $48.85, for a total transaction of $385,915.00.
  • On Tuesday, June 23rd, Herbert Virgin sold 5,560 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.99, for a total transaction of $216,784.40.
  • On Friday, June 19th, Herbert Virgin sold 3,510 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.00, for a total transaction of $133,380.00.
  • On Tuesday, June 9th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $36.28, for a total transaction of $138,045.40.
  • On Thursday, May 14th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $30.07, for a total transaction of $114,416.35.

Shares of Vir Biotechnology stock opened at $47.06 on Friday. Vir Biotechnology has a 1-year low of $11.65 and a 1-year high of $75.00. The firm’s 50-day moving average price is $43.38 and its two-hundred day moving average price is $33.15.

Vir Biotechnology (NYSE:VIR) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.18). The business had revenue of $5.72 million for the quarter, compared to analysts’ expectations of $3.21 million.

Institutional investors have recently modified their holdings of the business. Parallel Advisors LLC bought a new stake in Vir Biotechnology during the second quarter worth about $43,000. Citigroup Inc. grew its stake in Vir Biotechnology by 83.0% during the first quarter. Citigroup Inc. now owns 2,645 shares of the company’s stock worth $91,000 after buying an additional 1,200 shares during the last quarter. Advisor Group Holdings Inc. acquired a new position in shares of Vir Biotechnology during the first quarter worth approximately $96,000. Hoertkorn Richard Charles acquired a new position in shares of Vir Biotechnology during the second quarter worth approximately $166,000. Finally, Strs Ohio lifted its position in shares of Vir Biotechnology by 157.9% during the second quarter. Strs Ohio now owns 4,900 shares of the company’s stock worth $200,000 after purchasing an additional 3,000 shares in the last quarter.

A number of research firms recently weighed in on VIR. Barclays upped their target price on shares of Vir Biotechnology from $41.00 to $44.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Zacks Investment Research raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Wednesday, July 22nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $32.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: Guidelines for Successful Channel Trading

Insider Buying and Selling by Quarter for Vir Biotechnology (NYSE:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.